{"id":"https://openalex.org/W99521322","doi":null,"title":"CX-516 Cortex pharmaceuticals.","display_name":"CX-516 Cortex pharmaceuticals.","publication_year":2002,"publication_date":"2002-07-01","ids":{"openalex":"https://openalex.org/W99521322","mag":"99521322","pmid":"https://pubmed.ncbi.nlm.nih.gov/12186271"},"language":"en","primary_location":{"id":"pmid:12186271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12186271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060706996","display_name":"Wojciech Danysz","orcid":"https://orcid.org/0000-0003-2375-0210","observed_orcids":["https://orcid.org/0000-0003-2375-0210"]},"institutions":[{"id":"https://openalex.org/I4210113494","display_name":"Merz (Germany)","ror":"https://ror.org/025f1e779","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210113494"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Wojciech Danysz","raw_affiliation_strings":["Department of Behavioural Pharmacology, Merz & Co Pharmaceuticals GmbH, Frankfurt/Main, Germany. wojciech.danysz@merz.de"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Behavioural Pharmacology, Merz & Co Pharmaceuticals GmbH, Frankfurt/Main, Germany. wojciech.danysz@merz.de","institution_ids":["https://openalex.org/I4210113494"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5060706996"],"corresponding_institution_ids":["https://openalex.org/I4210113494"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"7","first_page":"1081","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.7461000084877014,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.20810000598430634,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.013799999840557575,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ampa-receptor-modulators","display_name":"AMPA receptor modulators","score":0.7789999842643738},{"id":"https://openalex.org/keywords/ampakines","display_name":"ampakines","score":0.8330000042915344},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.6589999794960022},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7210000157356262},{"id":"https://openalex.org/keywords/attention-deficit-hyperactivity-disorder","display_name":"attention deficit hyperactivity disorder","score":0.9179999828338623},{"id":"https://openalex.org/keywords/mild-cognitive-impairment","display_name":"mild cognitive impairment","score":0.9200000166893005},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9929999709129333},{"id":"https://openalex.org/keywords/neurotrophin-expression","display_name":"neurotrophin expression","score":0.8450000286102295},{"id":"https://openalex.org/keywords/drug-licensing-agreement","display_name":"drug licensing agreement","score":0.5889999866485596},{"id":"https://openalex.org/keywords/fragile-x-syndrome","display_name":"fragile X syndrome","score":0.5950000286102295},{"id":"https://openalex.org/keywords/autism-spectrum-disorder","display_name":"autism spectrum disorder","score":0.9860000014305115},{"id":"https://openalex.org/keywords/intellectual-property-strategy","display_name":"intellectual property strategy","score":0.3449999988079071}],"concepts":[{"id":"https://openalex.org/C2776863037","wikidata":"https://www.wikidata.org/wiki/Q662296","display_name":"Shire","level":2,"score":0.9563091993331909},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6885113716125488},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.6220806837081909},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5464233160018921},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.46547526121139526},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4584907591342926},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42640021443367004},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.37324804067611694},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06553038954734802},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001523","descriptor_name":"Mental Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D004149","descriptor_name":"Dioxoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004149","descriptor_name":"Dioxoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004149","descriptor_name":"Dioxoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:12186271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12186271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:99521322","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12186271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8560000061988831,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2342173701","https://openalex.org/W2001638562","https://openalex.org/W2049492562","https://openalex.org/W2069644503","https://openalex.org/W4238344548","https://openalex.org/W4237318284","https://openalex.org/W2473403452","https://openalex.org/W4413042898","https://openalex.org/W2414494173","https://openalex.org/W4206015401"],"abstract_inverted_index":{"CX-516":[0,37,110,156,193],"is":[1],"one":[2],"of":[3,6,23,82,88,96,109,177,182,192,259,285,308,317],"a":[4,77,105,112,131,188,222,264,321,334],"series":[5],"AMPA":[7],"modulators":[8],"under":[9,221,305],"development":[10,223],"by":[11],"Cortex,":[12],"in":[13,39,57,67,98,115,136,168,269],"collaboration":[14],"with":[15,120],"Shire":[16,161,170,185,202,228,234],"and":[17,28,46,61,129,147,162,224,246],"Servier,":[18],"for":[19,43,216,219,255,267],"the":[20,85,93,138,148,175,180,183,198,205,217,270,282,306,312],"potential":[21,95,265],"treatment":[22,176,266],"Alzheimer's":[24],"disease":[25],"(AD),":[26],"schizophrenia":[27,45,116],"mild":[29],"cognitive":[30],"impairment":[31],"(MCI)":[32],"[234221].":[33],"By":[34,242,288],"June":[35],"2001,":[36,73],"was":[38,63,75,102,124,141,151,171,301,327],"phase":[40,54,106,291],"II":[41,55,79,292],"trials":[42,293],"both":[44],"attention":[47],"deficit":[48],"hyperactivity":[49],"disorder":[50],"(ADHD)":[51],"[412513].":[52],"A":[53],"trial":[56,123],"fragile":[58],"X":[59],"syndrome":[60],"autism":[62],"expected":[64,280,328],"to":[65,91,103,125,142,152,172,207,230,252,329,331],"start":[66],"May":[68,289],"2002":[69],"[449861].":[70],"In":[71,158,297],"October":[72],"Cortex":[74,163,245,300],"awarded":[76,302],"Phase":[78],"SBIR":[80],"grant":[81],"$769,818":[83],"from":[84],"National":[86],"Institutes":[87],"Mental":[89],"Health":[90],"investigate":[92],"therapeutic":[94,323],"AMPAkines":[97,218],"schizophrenia.":[99],"This":[100,325],"award":[101],"support":[104],"IIb":[107],"study":[108,199,258],"as":[111,263,276],"combination":[113],"therapy":[114],"patients":[117,128],"concomitantly":[118],"treated":[119],"olanzapine.":[121],"The":[122],"enroll":[126],"80":[127],"employ":[130],"randomized,":[132],"double-blind,":[133,189],"placebo-controlled":[134,190],"design":[135],"which":[137,169],"placebo":[139,146],"group":[140,150],"receive":[143,153],"olanzapine":[144,154],"plus":[145,155],"active":[149],"[425982].":[157],"April":[159],"2000,":[160],"signed":[164],"an":[165,212,256,260],"option":[166,210],"agreement":[167],"evaluate":[173],"CX-516for":[174],"ADHD.":[178],"Under":[179],"terms":[181],"agreement,":[184,233],"would":[186,203,235],"undertake":[187],"evaluation":[191],"involving":[194],"ADHD":[195,220],"patients.":[196],"If":[197],"proved":[200],"effective,":[201],"have":[204],"right":[206],"convert":[208],"its":[209],"into":[211],"exclusive":[213],"worldwide":[214],"license":[215],"licensing":[225],"agreement.":[226],"Should":[227],"elect":[229],"execute":[231],"this":[232],"bear":[236],"all":[237],"future":[238],"developmental":[239],"costs":[240],"[363618].":[241],"February":[243],"2002,":[244,290,299],"Servier":[247],"had":[248],"revealed":[249],"their":[250],"intention":[251],"begin":[253],"enrolment":[254],"international":[257],"AMPAkine":[261],"compound":[262],"MCI":[268],"near":[271],"future.":[272],"Assuming":[273],"enrollment":[274],"proceeded":[275],"anticipated,":[277],"results":[278],"were":[279,294],"during":[281],"second":[283],"quarter":[284],"2003":[286],"[439301].":[287],"underway":[295],"[450134].":[296],"March":[298],"extended":[303],"funding":[304,326],"University":[307],"California":[309],"BioSTAR":[310],"projectfor":[311],"research":[313],"project:":[314],"'Ampakine":[315],"modulation":[316],"brain":[318],"neurotrophin":[319],"expression:":[320],"novel":[322],"strategy'.":[324],"amount":[330],"$193,000":[332],"over":[333],"two-year":[335],"period":[336],"[444872].":[337]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}